Cargando…
Is a PCSK9 Inhibitor Right for Your Patient? A Review of Treatment Data for Individualized Therapy
Introduction: In the United States, a significant amount of the population is affected by hyperlipidemia, which is associated with increased levels of serum low-density lipoprotein (LDL-C) and risk of cardiovascular disease. As of 2019, the guidelines set by the American College of Cardiology/Americ...
Autores principales: | Beltran, Roman A., Zemeir, Kyle J., Kimberling, Chase R., Kneer, Mary S., Mifflin, Michelle D., Broderick, Tom L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779535/ https://www.ncbi.nlm.nih.gov/pubmed/36554779 http://dx.doi.org/10.3390/ijerph192416899 |
Ejemplares similares
-
A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab
por: McDonagh, Marian, et al.
Publicado: (2016) -
FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017) -
Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020) -
Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021) -
Systematic review of published Phase 3 data on anti‐PCSK9 monoclonal antibodies in patients with hypercholesterolaemia
por: Gouni‐Berthold, Ioanna, et al.
Publicado: (2016)